Magnetic resonance spectroscopy in Alzheimer’s disease

Jonathan Graff-Radford¹
Kejal Kantarci²

¹Department of Neurology, ²Department of Radiology, Mayo Clinic, Rochester, MN, USA

Abstract: Aging is the primary risk factor for dementia. With increasing life expectancy and aging populations worldwide, dementia is becoming one of the significant public health problems of the century. The most common pathology underlying dementia in older adults is Alzheimer’s disease. Proton magnetic resonance spectroscopy (MRS) may provide a window into the biochemical changes associated with the loss of neuronal integrity and other neurodegenerative pathology that involve the brain before the manifestations of cognitive impairment in patients who are at risk for Alzheimer’s disease. This review focuses on proton MRS studies in normal aging, mild cognitive impairment, and dementia, and how proton MRS metabolite levels may be potential biomarkers for early diagnosis of dementia-related pathologic changes in the brain.

Keywords: Alzheimer’s disease, magnetic resonance spectroscopy, mild cognitive impairment

Introduction

Biomarkers of Alzheimer’s disease (AD) are important for both early diagnoses and evaluating treatment effects. Three decades of research indicate that proton magnetic resonance spectroscopy (MRS) is a potential biochemical imaging marker in AD. The focus of this review is to discuss the role of proton MRS in Alzheimer’s disease. MRS allows regional measurement of metabolites including myo-Inositol (mI), choline (Cho), N-acetyl aspartate (NAA), and creatine (Cr). Cr is typically used as an internal reference to control for variability in measurement because it remains unchanged in AD.¹⁻³ Other metabolites that can be measured with proton MRS with advanced MRS sequences and post-processing methods include gamma-Aminobutyric acid (GABA) and glutathione which may not be available in conventional clinical scanners and are not the focus of this review. MRS may serve to identify patients with AD before clinical symptom onset as well as help distinguish AD from other neurodegenerative disorders.

Development of metabolic biomarkers for AD

In 1992, Klunk et al⁴ demonstrated a decrease in the neuronal metabolite NAA on MRS on autopsy brain samples of patients with AD compared to controls. The lower NAA level correlated with the amount of plaque and tangle pathology.⁴ NAA is considered a neuronal marker and is synthesized in mitochondria.⁵ Supporting the notion that NAA levels correspond to neuronal integrity, reduced NAA levels in cortical tissue from patients with AD demonstrated a correlation between NAA concentration and neuronal density.⁶ Decreased NAA seen in head trauma, seizure, or coronary artery bypass
surgery can resolve after recovery.\textsuperscript{5,7–9} Further, NAA levels decreased in AD show transient improvement with acetylcholinesterase inhibitor treatment.\textsuperscript{10} The neurofibrillary tangles pathology of AD follow a typical progression from limbic to neocortical areas as AD advances.\textsuperscript{11} Similarly, changes in NAA follow a regional pattern as disease advances. For example, AD patients show a regional decrease in NAA/Cr ratio in the superior temporal lobe and posterior cingulate voxels compared to controls, but mild cognitive impairment (MCI) patients do not show a decline in NAA/Cr as AD-related neurodegeneration has not yet extended to these regions.\textsuperscript{12} Medial occipital lobe AD pathology involvement typically occurs at the final stage of the disease.\textsuperscript{11} Therefore, it is not surprising that there is no regional decrease in NAA/Cr in mild AD in the occipital lobe while more advanced cases demonstrate decrease NAA/Cr ratio.\textsuperscript{12–14} Eventually, NAA changes become widespread and have been shown to involve the parietal, temporal, and frontal lobe.\textsuperscript{12,15–19} Decreased NAA/Cr ratios are non-specific and can be seen in other types of dementia including normal pressure hydrocephalus and have even been reported in cognitive decline associated with acquired immunodeficiency syndrome (AIDS).\textsuperscript{20,21}

In 1993, it was demonstrated that in addition to decreased NAA levels, AD patients have elevated myo-Inositol to creatine (ml/Cr) levels.\textsuperscript{13} While NAA is a neuronal marker, ml is associated with glia and elevated levels with glial proliferation.\textsuperscript{22,23} The finding of decreased NAA and elevated ml in AD has been confirmed in several studies.\textsuperscript{12,16,24}

The role of choline metabolite in AD is more controversial. A number of studies demonstrated increased choline in AD.\textsuperscript{25–27} Other studies have demonstrated no change in choline concentration in AD compared to controls.\textsuperscript{28–31} One study reported a decrease of choline/H\textsubscript{2}O in the medial temporal lobes of AD patients.\textsuperscript{32} Brain choline is concentrated in phospholipids. The choline peak in MRS represents cytosolic glycerophosphocholine and phosphocholine which are breakdown products of phosphatidylcholine.\textsuperscript{33} Therefore the larger choline peak may be due to increased membrane turnover. Also, it has been proposed that catabolism of the phospholipid membrane bilayer allows AD subjects to produce choline to compensate for declining acetylcholine.\textsuperscript{34} Administration of xanomeline, an M1 selective muscarinic cholinergic agonist, to AD patients resulted in a significant decline in Cho/Cr ratios, perhaps representing a reduction in compensatory mechanisms to produce acetylcholine through phospholipid breakdown.\textsuperscript{35} Cho/Cr increases in amnestic MCI if it progresses to AD but the ratio decreases if cognition remains stable.\textsuperscript{36} Decreased glutamate (Glu) or glutamate + glutamine/Cr ratio has also been found in the grey matter of AD patients, but not the white matter.\textsuperscript{37–40} Furthermore, increased Glu and the ratio of Glu to Cr measured from the hippocampus by MRS after galantamine treatment were associated with increased cognitive performance.\textsuperscript{41} MRS studies in transgenic mice with AD mutations have shed light on the pathological correlates of metabolite changes seen in AD. Transgenic mice with AD mutations demonstrate similar decreased NAA and increased ml as seen in human AD patients.\textsuperscript{6,42} In addition, lower NAA and glutamate levels correlate with amyloid beta (A\textbeta) plaque load in the frontal cortex of mice with PS2APP mutation.\textsuperscript{43} Further, the MRS metabolite changes consistent with AD precede overt cognitive dysfunctions in early-stage AD.\textsuperscript{44}

The temporal progression of metabolite abnormalities in AD are characterized by an increased ml/Cr followed by a decrease in NAA/Cr and an increase in Cho/Cr.\textsuperscript{12} A recent study of pathologic correlates of MRS metabolite changes in cases of varying AD pathology demonstrated that ante-mortem NAA/Cr and ml/Cr levels correlate with the pathologic severity of AD, and that the strongest predictor of AD pathology was a NAA/ml ratio.\textsuperscript{45} Longitudinal studies have demonstrated that NAA/Cr and NAA/ml decrease over time compared to controls.\textsuperscript{36,46,47}

NAA/Cr and ml/Cr ratios correlate with cognitive testing in Alzheimer's disease.\textsuperscript{16,17,24,48–51} In one study, NAA/Cr in the medial temporal lobe, primary motor and sensory cortices correlated with Mini-Mental State Examination and the cognitive part of the Alzheimer Disease Assessment Scale scores.\textsuperscript{16} NAA/Cr, ml/Cr, NAA/ml have also been shown to correlate with verbal memory testing (Auditory Verbal Learning Test) and general cognition (Dementia Rating Scale).\textsuperscript{50}

Several studies have investigated the ability of MRS to distinguish AD patients from controls with varying results depending on the anatomic area analyzed and acquisition parameters. The sensitivity was as high as 90% in the temporalparietal region and as low as 57% in the parietal lobe grey matter. The specificity was as high as 95% in the medial occipital lobe and as low as 73% in the posterior cingulate.\textsuperscript{14,19,52–54} Furthermore, adding hippocampal volume to MRS, improves the ability to distinguish AD.\textsuperscript{19,53–56}

A few studies with relatively small sample sizes have investigated MRS as a biomarker for treatment response in AD. NAA/Cr improved after acetylcholinesterase inhibitor treatment in AD.\textsuperscript{10,28} Another trial showed decreases in Cho/Cr and ml/Cr in the hippocampus in absence of clinical
improvement in AD subjects, however, this study showed continued decrease in NAA/Cr in contrast to the studies mentioned above.\(^{39}\)

MRS also correlates with psychiatric symptoms in AD patients. AD subjects with psychosis have significantly reduced cortical NAA compared to AD subjects without psychosis.\(^{57}\) Psychiatric and behavioral symptoms in AD including delusional thinking correlated with a decrease in NAA/Cr and an increase in ml/Cr in the anterior cingulate.\(^{58}\)

### MRS for MCI

NAA/Cr levels in MCI are mildly reduced but decline as patients with MCI progress to AD.\(^{36}\) Further, lower NAA/Cr in MCI patients predicts progression to AD.\(^{36,59,60}\) Cho/Cr and ml/Cr levels are also elevated in the posterior cingulate in MCI although higher levels of these metabolites are detected in AD.\(^{12}\) The Cho/Cr ratio is also useful in determining progression from MCI to AD. In MCI patients, a decline in Cho/Cr predicted stability versus an increase, which predicted conversion to AD. The changes in metabolite concentration on MRS correlate as strongly as ventricular volume in predicting cognitive decline.\(^{36}\)

MRS is also useful in distinguishing subtypes of MCI. Amnestic MCI patients have smaller hippocampi with elevated ml/Cr ratios compared to patients with non-amnestic MCI in line with the observation that amnestic MCI patients are more likely to progress to AD than non-amnestic MCI.\(^{61}\)

### MRS based identification of biomarkers for other neurological disorders, to distinguish from AD

The main differential diagnoses of Alzheimer’s dementia are other types of dementia including dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VaD). The MRS signature of AD is decreased NAA/Cr and elevated Cho/Cr and ml/Cr metabolites.\(^{25}\) Several studies have investigated the metabolite patterns among different types of dementia in order to identify patterns of metabolite changes unique to each dementia.

Many patients with dementia have significant overlap in underlying pathology.\(^{62}\) In patients with VaD, the location of the metabolite change is important for distinguishing VaD from AD. For example, NAA levels in VaD are decreased in a similar way to those in AD patients and the decrease is greater than AD in the white matter.\(^{63-65}\) Unlike AD, cortical ml is normal in VaD.\(^{66,67}\) Further, ml/Cr is higher in AD compared to VaD.\(^{25}\) Therefore, ml and grey matter NAA may serve as useful markers to distinguish AD from VaD.

Similar to AD, FTD is associated with elevated ml/Cr and decreased NAA/Cr.\(^{68,69}\) Despite the similarities, regional differences in metabolites may help distinguish the two dementias. Compared to early AD, patients with FTD have higher ml/Cr and lower NAA/Cr in the frontal cortex.\(^{68,70}\) However, others have noted no difference between FTD and AD with similar levels of metabolite abnormalities outside the frontal lobes.\(^{25}\)

Similar to the other dementias, significant overlap exists between DLB and AD. Compared to other dementia subtypes, DLB has a normal NAA/Cr ratio in the posterior cingulate.\(^{25}\) The normal NAA/Cr is possibly related to the relative preservation of neurons in DLB compared to AD.\(^{71}\) In the hippocampus of DLB patients, the NAA has been reported to be decreased although it is unclear if this decrease represents concomitant AD given the overlap in pathologies mentioned above.\(^{72}\) Additionally, NAA is similarly decreased in the white matter of patients with DLB.\(^{73}\) Therefore, NAA levels in the posterior cingulate may help distinguish AD from DLB. The relative preservation of the cingulate is in agreement with fluorodeoxyglucose (FDG) positron emission tomography (PET) which demonstrates a relative preservation of glucose metabolism in the cingulate of DLB when compared to AD.\(^{74}\)

Similar to AD, DLB patients have an elevated Cho/Cr compared to controls.\(^{25}\) This finding is intriguing because both AD and DLB are characterized by a cholinergic deficit.\(^{75}\) Since Cho/Cr levels decrease with cholinergic agonist treatment in AD,\(^{15}\) the decrease raises the possibility that Cho/Cr can be used as a therapeutic biomarker in AD and DLB.

In summary, while significant overlap exists between dementias, AD has a unique metabolite pattern compared to other dementias when regional differences are taken into account.

### Current place of MRS in the differential diagnosis of AD

The American Academy of Neurology practice parameter recommends against routine imaging with quantitative MRI techniques in the evaluation of dementia because of insufficient evidence.\(^{76}\) Nonetheless, as a research tool, MRS can provide valuable information in the differential diagnoses of dementia. AD biomarkers, such as Amyloid PET imaging and cerebrospinal fluid Aβ, provide useful information about whether AD is the pathology underlying a given dementia. MRS can provide complementary predictive information. In addition, MRS allows for identification of a metabolite signature of different dementia subtypes which can provide
Table 1 In vivo studies with MRS in AD and MCI

<table>
<thead>
<tr>
<th>Authors</th>
<th>Disease</th>
<th>Acquisition parameters</th>
<th>Magnet field strength</th>
<th>Single voxel locations</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schuff et al17</td>
<td>AD</td>
<td>TR/TE = 1800/135 ms</td>
<td>1.5 T</td>
<td>Frontal, middle, posterior mesial cortex</td>
<td>Decreased NAA frontal and posterior mesial cortex.</td>
</tr>
<tr>
<td>Zhu et al17</td>
<td>AD</td>
<td>TR/TE = 1800/25 ms</td>
<td>1.5 T</td>
<td>Parietal GM, frontal GM, parietal WM, and frontal WM</td>
<td>Decreased NAA/CR parietal/frontal GM and parietal WM.</td>
</tr>
<tr>
<td>Schuff et al31</td>
<td>AD</td>
<td>TR/TE = 1800/135 ms</td>
<td>1.5 T</td>
<td>Hippocampus</td>
<td>Increased ml/CM in parietal GM.</td>
</tr>
<tr>
<td>Frederick et al35</td>
<td>AD</td>
<td>TR/TE = 2000/272 ms</td>
<td>Not reported</td>
<td>Parietal, temporal lobes</td>
<td>Decreased NAA/CR hippocampus.</td>
</tr>
<tr>
<td>Jessen et al36</td>
<td>AD</td>
<td>TR/TE = 2000/272 ms</td>
<td>1.5 T</td>
<td>Medial temporal lobe and the primary motor and sensory cortex</td>
<td>Decreased NAA/CR temporal lobe compared to controls.</td>
</tr>
<tr>
<td>Huang et al24</td>
<td>AD</td>
<td>TR/TE = 3000/30 ms</td>
<td>1.5 T</td>
<td>Occipital and parietal regions</td>
<td>Decreased NAA/CR in occipital and parietal regions in AD which changes with severity. Increased ml/Cr in occipital and parietal regions even in mild AD. AD and MCI demonstrated reductions of NAA/H2O and Cho/H2O in the left MTL, ml/Cr increased in AD relative to MCI and controls in medial temporal lobe. NAA/CR AD &lt; MCI = control, ml/CM/AD &gt; Controls.</td>
</tr>
<tr>
<td>Chantal et al50</td>
<td>AD and MCI</td>
<td>TR/TE = 1200/50 ms</td>
<td>1.5 T</td>
<td>Medial temporal lobes, parietotemporal cortices and prefrontal cortices</td>
<td>NAA/CR positively correlated and ml/CM negatively correlated to cognitive tests in the posterior but not anterior cingulate. Behavioral symptoms of dementia negatively related with NAA/CR and positively related with ml/CM in the anterior cingulate gyrus, but not in the posterior cingulate.</td>
</tr>
<tr>
<td>Kantarci et al50</td>
<td>AD and MCI</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate</td>
<td>Rivastigmine treatment reversed NAA/CR decrease in frontal cortex only.</td>
</tr>
<tr>
<td>Shinno et al58</td>
<td>AD</td>
<td>TR/TE = 1500/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate, anterior cingulate</td>
<td>Rivastigmine treatment reversed NAA/CR decrease in frontal cortex only.</td>
</tr>
<tr>
<td>Modrego et al10</td>
<td>AD</td>
<td>TR/TE = 2500/30 ms</td>
<td>1.5 T</td>
<td>Frontal, parietal and occipital cortices</td>
<td>Decreased NAA/CR in occipital GM and parietal WM in AD.</td>
</tr>
<tr>
<td>Miller et al13</td>
<td>AD</td>
<td>TR/TE = 1500/30 ms</td>
<td>1.5 T</td>
<td>Parietal WM and occipital GM</td>
<td>Increased ml/CM in occipital GM and parietal WM.</td>
</tr>
<tr>
<td>Shonk et al14</td>
<td>AD</td>
<td>TR/TE = 1500/30 ms</td>
<td>Not reported</td>
<td>Occipital grey matter</td>
<td>Reduced NAA/CR and increase in ml/CM in occipital grey matter in AD.</td>
</tr>
<tr>
<td>Tedeschi et al18</td>
<td>AD</td>
<td>TR/TE = 2200/272 ms</td>
<td>1.5 T</td>
<td>Frontal, temporal, parietal, occipital, and insular cortices, subcortical WM, and thalamus</td>
<td>Reduction of NAA/CR in the frontal, temporal, parietal cortices in AD.</td>
</tr>
<tr>
<td>Kantarci et al25</td>
<td>AD</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate</td>
<td>Reduction of CHO/CR in the WM.</td>
</tr>
<tr>
<td>Meyerhoff et al26</td>
<td>AD</td>
<td>Not reported</td>
<td>2 T</td>
<td>Centrum semiovale containing white and mesial grey matter</td>
<td>Increased ml/CM and elevated CHO/CR in AD compared to controls.</td>
</tr>
<tr>
<td>Krishnan et al28</td>
<td>AD</td>
<td>TR/TE = 1200/35 ms</td>
<td>1.5 T</td>
<td>Subcortical gray, periventricular, cortical, and WM at the level of the third ventricle</td>
<td>Reduced NAA/CR and increase in ml/CM and elevated CHO/CR in AD compared to controls.</td>
</tr>
<tr>
<td>Rose et al30</td>
<td>AD</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Parietal lobes</td>
<td>Elevated NAA in the donepezil-treated compared to placebo controls.</td>
</tr>
<tr>
<td>Satlin et al35</td>
<td>AD</td>
<td>TR/TE = 2 sec/272 ms</td>
<td>1.5 T</td>
<td>Parietal lobe</td>
<td>NA/CR was significantly reduced in the AD group with increase in ml/CM.</td>
</tr>
<tr>
<td>Kantarci et al36</td>
<td>AD and MCI</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate</td>
<td>Metabolite measures also correlated with atrophy.</td>
</tr>
<tr>
<td>Hattori et al36</td>
<td>AD</td>
<td>TR/TE = 6 s/25 ms</td>
<td>3 T</td>
<td>Posterior cingulate gyrus and the precuneus and parietooccipital WM</td>
<td>For patients taking xanomeline, there was a decrease in CHO/CR.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NAA/CR declined in MCI and AD patients compared to controls. Cho/CR declined in stable MCI, compared to converter MCI patients.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA/CR decreased in both regions in AD. Decrease in the glutamate/Glu/CR and were detected in the grey matter, but not in the white matter.</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Disease</td>
<td>TR/TE</td>
<td>Field</td>
<td>Region</td>
<td>Findings</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Bartha et al.</td>
<td>AD</td>
<td>TR/TE = 3200/46 ms</td>
<td>4 T</td>
<td>Hippocampus</td>
<td>Decreased NAA/Cr, Cho/Cr, and ml/Cr were observed in AD patients after 4 months of donepezil treatment. Subjects with AD had decreased glutamate as well as decreased Glu/Cr, Glu/ml, Glu/NAA, and NAA/Cr ratios compared to controls. Levels of Glu, Glu/Cr, and Glu/NAA increased after 4 months of treatment with galantamine compared to controls. Decreased NAA/Cr in post cingulate. Increased ml/Cr in post cingulate. NAA/ml declines over time in AD compared to controls. NAA/Cr was reduced in the hippocampus of MCI and AD. AD had elevated ml/Cr PGM, reduced NAA/Cr in PWM.</td>
</tr>
<tr>
<td>Rupsingh et al.</td>
<td>AD</td>
<td>TR/TE = 2.2 s/46 ms</td>
<td>4 T</td>
<td>Hippocampus</td>
<td></td>
</tr>
<tr>
<td>Penner et al.</td>
<td>AD</td>
<td>TR/TE = 3200/46 ms</td>
<td>4 T</td>
<td>Right hippocampus</td>
<td></td>
</tr>
<tr>
<td>Schott et al.</td>
<td>AD</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate</td>
<td></td>
</tr>
<tr>
<td>Akdl et al.</td>
<td>AD and MCI</td>
<td>TR/TE = 2000/35 ms for the parietal white and grey matter and TE = 70 ms for the hippocampus on the left cerebral hemisphere</td>
<td>1.5 T</td>
<td>Parietal gray and white matter and the hippocampus</td>
<td>NAA concentration was less in AD in the medial temporal lobe and parietal grey matter, but not white matter and frontal lobe GM. Lower NAA, AD patients had smaller hippocampi and less cortical GM. Patients with MCI who progressed to dementia had lower NAA/Cr at baseline than stable MCI. NAA/Cr can predict conversion from MCI to dementia. Lower NAA/Cr compared to controls. High Cho/Cr in posterior regions compared to controls. Lower NAA/Cr in VaD compared to controls. Compared to controls, VaD had lower NAA in frontal and parietal cortex. Compared to patients with AD, VaD had lower NAA in frontal cortex and parietal cortex. AD had higher ml/Cr compared to those with VaD and normal subjects. NAA/Cr reduced in the posterior cingulate cortex in AD and FTD. AD showed a posterior dominant decrease, whereas FTD showed a frontal decrease. FTD showed reduced NAA and glutamate plus glutamine and increased ml. In AD, no abnormalities were observed in the frontal region, but ml was elevated in the temporoparietal region.</td>
</tr>
<tr>
<td>Schuff et al.</td>
<td>AD</td>
<td>TR/TE = 1800/135 ms</td>
<td>1.5 T</td>
<td>Medial temporal, frontal, parietal gray and white matter</td>
<td></td>
</tr>
<tr>
<td>Metastasio et al.</td>
<td>MCI</td>
<td>TR/TE = 2000/40 ms</td>
<td>1.5 T</td>
<td>Paratrigonal WM</td>
<td></td>
</tr>
<tr>
<td>Kantarci et al.</td>
<td>MCI</td>
<td>TR/TE = 2000/30 ms</td>
<td>1.5 T</td>
<td>Posterior cingulate</td>
<td></td>
</tr>
<tr>
<td>Mckay et al.</td>
<td>AD and VaD</td>
<td>TR/TE = 3000/30 and 80 ms</td>
<td>2 T</td>
<td>Anterior, medial, and posterior GM and WM</td>
<td></td>
</tr>
<tr>
<td>Schuff et al.</td>
<td>AD and VaD</td>
<td>TR/TE = 1800/135 ms</td>
<td>1.5 T</td>
<td>Frontal, parietal, temporal cortex</td>
<td></td>
</tr>
<tr>
<td>Waldman et al.</td>
<td>AD, VaD</td>
<td>TR/TE = 1500/30 ms</td>
<td>1 T</td>
<td>Occipital GM</td>
<td></td>
</tr>
<tr>
<td>Mihara et al.</td>
<td>AD, FTD</td>
<td>TR/TE = 6000/25 ms</td>
<td>3 T</td>
<td>Posterior and anterior cingulate cortices and the parietooccipital and frontal white matter</td>
<td>NAA/Cr reduced in the posterior cingulate cortex in AD and FTD. AD showed a posterior dominant decrease, whereas FTD showed a frontal decrease.</td>
</tr>
<tr>
<td>Ernst et al.</td>
<td>AD, FTD</td>
<td>TR/TE = 3000/30 ms</td>
<td>1.5 T</td>
<td>Midfrontal and temporoparietal gray matter</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AD, Alzheimer's disease; Cho, choline; Cr, creatine; FTD, frontotemporal dementia; Glu, glutamate; GM, grey matter; ml, myo-inositol; MCI, mild cognitive impairment; NAA, N-acetyl aspartate; PGM, parietal grey matter; PWM, parietal white matter; T, tesla; TE, echo time; TR, repetition time; WM, white matter; VaD, vascular dementia.
complementary data to the clinical impression. To date, no MRS study has used metabolite signature in conjunction with regional differences to determine the underlying pathology.

**Utility of MRS along with other AD biomarkers**

In 2011, the National Institute on Aging and Alzheimer’s Association revised criteria for preclinical, MCI, and Alzheimer’s disease. The pathology that contributes to AD begins to accumulate years before clinical symptoms. Therefore, identifying the population at high risk of developing symptoms has become important. Principal AD imaging biomarkers include Aβ imaging with PET, FDG-PET, and structural MRI. In cognitively normal older adults, ml/Cr and Cho/Cr correlate with Aβ load in amyloid PET imaging as demonstrated in two example cases with high and low Aβ load in their brains in Figure 1.

According to one model of biomarkers in AD, amyloid pathology accumulates before evidence of neurodegeneration. Amyloid PET imaging serves as a surrogate for brain amyloid load and FDG-PET and Structural MRI serve as markers of neurodegeneration. While these imaging markers are well validated measures of amyloid and neurofibrillary tangle pathology, they do not measure microglial activation. MRS ml is a potential surrogate marker for glial activity. A recent 13-carbon MRS and 1H MRS linked glial and microglial activity to ml elevation in AD.

**Figure 1** Association between MRS metabolite ratios and cortical Pittsburgh compound-B (PiB) retention ratio on PET.

**Notes:** The left panel shows the PiB retention ratio PET images in an 82-year-old man with a PiB retention ratio of 2.42, NAA/Cr ratio of 1.51, ml/Cr ratio of 0.58, and Cho/Cr ratio of 0.76. The right panel shows the PiB retention ratio PET images in an 82-year-old woman with a PiB retention ratio of 1.27, NAA/Cr ratio of 1.69, ml/Cr ratio of 0.45, and Cho/Cr ratio of 0.54. The spectra are scaled to the Cr peak. High PiB retention is associated with significantly elevated ml/Cr and Cho/Cr ratio and a trend of lower NAA/Cr ratio.

**Abbreviations:** Cho, choline; Cr, creatine; ml, myo-inositol; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; PET, positron emission tomography.

---

Graff-Radford and Kantarci

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ by 54.70.40.11 on 08-Dec-2018

For personal use only.
This raises the possibility that elevated mI represents inflammation which is an early event in the evolution of AD pathology.2

While hippocampal atrophy predicts AD pathology and is an imaging marker of neurodegeneration in the National Institute on Aging – Alzheimer’s Association (criteria for preclinical AD),34,35 up to 11% of AD cases are hippocampal sparing, with corresponding preserved hippocampal volumes on MRI.46-49 Subjects with at least one type of hippocampal sparing AD (posterior cortical atrophy), have been demonstrated to have decreased NAA/Cr in the posterior cingulate.90 Therefore, MRS may serve a role as a critical marker of AD pathology in a significant minority of AD cases where the hippocampus is relatively preserved. Other imaging markers that may provide important information in atypical AD cases include resting state functional MRI, and diffusion tensor imaging (DTI). Cognitive testing may provide additional information.

MRS can serve as a predictor of the degree of AD pathology in clinical trial design. For example, mI/Cr is elevated in MCI and mild AD even with normal NAA/Cr.12,24,89 In addition, isolated mI/Cr elevation is associated with earlier stage AD pathology compared to elevated mI and decrease in NAA/Cr which is associated with a later stage AD pathology. Isolated elevation in mI/Cr can be seen prior to structural MRI changes in individuals with familial dementia prior to symptom onset.90 Therefore, MRS could potentially serve as an adjunct to help select patients for intervention trials based on degree of AD pathology.

In addition to serving as a potential marker of glial activity, MRS can be used along with other biomarkers as a tool to predict cognitive decline. In a group of cognitively normal individuals, elevated Cho/Cr in the white matter predicts progression to dementia.91 The metabolite formula changes in preclinical familial AD families with amyloid precursor protein, presenilin 1 or 2 mutations. Asymptomatic mutation carriers demonstrated elevated mI/Cr and decreased NAA/Cr with reduction in NAA/mI correlating with nearness to age of onset.92 In addition to serving as a marker of preclinical disease, MRS has utility in monitoring disease progression. NAA/Cr levels predict cognitive decline in individuals with AD.36,46,93

Future predictions for the use of MRS in the differential diagnosis of AD

While much progress has been made in understanding the role of MRS in Alzheimer’s disease, MRS is still not routinely used clinically in the assessment of dementia. Reasons for ineffective translation of technology to clinical practice or patient-oriented research are twofold: (1) Lack of standardization for multi-site applications and normative data; and (2) insufficient understanding of the pathologic basis of 1H MRS metabolite changes.94 Although metabolite abnormalities in AD have been demonstrated in different samples and in pathologically confirmed cases, the pathological substrates for these metabolite abnormalities are not fully understood.

Future studies are needed to elucidate the pathological significance of these metabolite changes in AD. As we learn more about the pathophysiology of the underpinnings of the metabolite abnormalities, the routine use of MRS as a biomarker will become more prevalent.

Acknowledgment

Grant support: Dr Kantarci’s research program is supported by the National Institutes of Health: R01 AG40042, P50 AG16574/Project1, P50AG044170/Project 2, and R21 NS066147. The authors would like to acknowledge Samantha Wille for manuscript preparation.

Disclosure

Dr Kantarci serves on the data safety monitoring board for Pfizer Inc, and Janssen Amyloid Immunotherapy and Takeda Global Research and Development Center, Inc; she is funded by the National Institutes of Health (R01AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], and R01 AG11378 [Co-I]).

Dr Graff-Radford reports no conflicts of interest in this work.

References


